Completed PHASE2 INTERVENTIONAL 2-arm NCT01290315

Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

A Randomized, Controlled Study to Investigate the Safety and Oxidative Stress Potential of Intravenous Ferric Carboxymaltose (FCM) vs. IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women

Sponsor: American Regent, Inc.

Conditions Iron Deficiency Anemia

Interventions Ferric Carboxymaltose (FCM) Iron Sucrose / Iron Dextran

Updated 8 times since 2017 Last updated: Feb 2, 2018 Started: Aug 31, 2009 Primary completion: Mar 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Iron Deficiency Anemia and is currently completed. American Regent, Inc. leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Mar 2018 — Jun 2018 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Feb 2017 — Mar 2018 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Regent, Inc.

Data source: American Regent, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norristown, United States